EVT-103 explained

Routes Of Administration:	By mouth
Class:	NMDA receptor antagonist
Cas Number:	2457151-78-7
Synonyms:	ENS-103

EVT-103, also known as ENS-103, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.^[1] It acts as an NMDA receptor subunit 2B (NR2B) antagonist. As of November 2017, no recent reports of development for major depressive disorder have been identified. The drug was developed as a follow-up compound to EVT-101.^[2] The chemical structure of EVT-103 has not been released.

See also

• List of investigational antidepressants

Notes and References

1. Web site: EVT 103 . AdisInsight . Springer Nature Switzerland AG .
2. Book: Ruppa KB, King D, Olson RE . Annual Reports in Medicinal Chemistry Volume 47. NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C, and GluN2D Subtypes—Recent Results and Developments. 47. 2012. 89–103. 0065-7743. 10.1016/B978-0-12-396492-2.00007-2. 9780123964922.